Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)

Kamer S., Ren Q., Dicker A. P.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.279, no.1, pp.41-46, 2009 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 279 Issue: 1
  • Publication Date: 2009
  • Doi Number: 10.1007/s00404-008-0667-7
  • Page Numbers: pp.41-46


Cervical cancer is one of the deadliest cancers in women with a death toll of 230,000 worldwide each year, nearly 80% in developing countries. Radiotherapy (RT) is a major treatment modality for advanced cervical cancer but the local relapse rate is 30-44% in patients treated with RT alone and 19-25% in patients treated with concurrent chemoradiotherapy. Previous studies have shown that the transcription factor NF-kappa B is constitutively expressed in human cervical squamous cell carcinomas. NF-kappa B activation also contributes to the resistance of cervical cancer cells to apoptosis induced by chemotherapeutic agents and radiation. Therefore, inhibition of NF-kappa B in tumor cells may render them more sensitive to chemo/radiation therapies. The objective of this study is to investigate the potential of radiosensitization of NF-kappa B inhibition by Velcade in human cervical cancer cell lines.